An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis.

@article{Crooke2005AnAB,
  title={An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis.},
  author={Rosanne M. Crooke and Mark J. Graham and Kristina M. Lemonidis and Charles P. Whipple and Seonjoon Koo and Ranjan J Perera},
  journal={Journal of lipid research},
  year={2005},
  volume={46 5},
  pages={
          872-84
        }
}
High levels of plasma apolipoprotein B-100 (apoB-100), the principal apolipoprotein of LDL, are associated with cardiovascular disease. We hypothesized that suppression of apoB-100 mRNA by an antisense oligonucleotide (ASO) would reduce LDL cholesterol (LDL-C). Because most of the plasma apoB is made in the liver, and antisense drugs distribute to that organ, we tested the effects of a mouse-specific apoB-100 ASO in several mouse models of hyperlipidemia, including C57BL/6 mice fed a high-fat… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 116 CITATIONS, ESTIMATED 45% COVERAGE

Emerging options in the treatment of dyslipidemias: a bright future?

VIEW 5 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Development of Apolipoprotein B Antisense Molecules as a Therapy for Hyperlipidemia

VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Antisense therapy in the treatment of hypercholesterolemia.

VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Mipomersen, an antisense apolipoprotein B synthesis inhibitor.

VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2003
2019

CITATION STATISTICS

  • 7 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 61 REFERENCES

Intracellular assembly of VLDL. Two major steps in separate cell compartments

  • Oloffson S-V, P. Stillemark-Billton, L. Asp
  • Trends Cardiovasc. Med
  • 2001
VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL

Pharmacokinetic properties of 2′-O-(2-methoxylethyl)modified oligonucleotide analogs in rats

  • Geary R.S, T. A. Watanabe, +6 authors A. A. Levin
  • J. Pharmacol. Exp. Ther
  • 2001
VIEW 16 EXCERPTS
HIGHLY INFLUENTIAL